oliviaeex personal page - To The Moon

oliviaeex

oliviaeex

No personal profile

0Follow

23Followers

0Topic

0Badge

2021-09-13

oh dear

Sorry, the original content has been removed

2021-07-30

PHAR IS DA WAY

After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%

2021-07-21

trump crumbs

Sorry, the original content has been removed

2021-07-20

meaning of drug deals

Sorry, the original content has been removed

2021-07-16

Me had moderna vaccine

Why Moderna Stock Is Hitting Another Record High Today

2021-04-27

Netflix > Disney+

Sorry, the original content has been removed

2021-04-23

like for like

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3581502293537821","uuid":"3581502293537821","gmtCreate":1618408736929,"gmtModify":1618885052710,"name":"oliviaeex","pinyin":"oliviaeex","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":23,"headSize":0,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.30","exceedPercentage":"80.16%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":888241656,"gmtCreate":1631502260075,"gmtModify":1676530559601,"author":{"id":"3581502293537821","authorId":"3581502293537821","name":"oliviaeex","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581502293537821","authorIdStr":"3581502293537821"},"themes":[],"htmlText":"oh dear","listText":"oh dear","text":"oh dear","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/888241656","repostId":"1104432279","repostType":4,"isVote":1,"tweetType":1,"viewCount":764,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808557517,"gmtCreate":1627603432839,"gmtModify":1703493081019,"author":{"id":"3581502293537821","authorId":"3581502293537821","name":"oliviaeex","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581502293537821","authorIdStr":"3581502293537821"},"themes":[],"htmlText":"PHAR IS DA WAY","listText":"PHAR IS DA WAY","text":"PHAR IS DA WAY","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/808557517","repostId":"2155182860","repostType":4,"repost":{"id":"2155182860","kind":"news","pubTimestamp":1627603020,"share":"https://ttm.financial/m/news/2155182860?lang=&edition=fundamental","pubTime":"2021-07-30 07:57","market":"us","language":"en","title":"After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2155182860","media":"StreetInsider","summary":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food an","content":"<p>After-Hours Stock Movers:</p>\n<p>ERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).</p>\n<p>Atlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.</p>\n<p>Misonix, Inc. (Nasdaq: MSON) 12% HIGHER; <a href=\"https://laohu8.com/S/BIOV\">Bioventus Inc.</a> (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.</p>\n<p><a href=\"https://laohu8.com/S/ZYXI\">Zynex, Inc.</a> (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.</p>\n<p>Zendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.</p>\n<p>Skyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.</p>\n<p>DexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: ERYTECH Pharma shares jumped 140%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: ERYTECH Pharma shares jumped 140%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744154><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744154\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSON":"Misonix Inc","DXCM":"德康医疗","TEAM":"Atlassian Corporation PLC","SWKS":"思佳讯","ZEN":"Zendesk Inc.","ZYXI":"Zynex, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744154","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155182860","content_text":"After-Hours Stock Movers:\nERYTECH Pharma (Nasdaq: ERYP) 140% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).\nAtlassian (NASDAQ: TEAM) 13.2% HIGHER; reported Q4 EPS of $0.24, $0.06 better than the analyst estimate of $0.18. Revenue for the quarter came in at $560 million versus the consensus estimate of $524.09 million. Atlassian sees Q1 2022 EPS of $0.38-$0.39, versus the consensus of $0.31. Atlassian sees Q1 2022 revenue of $575-590 million, versus the consensus of $540.89 million.\nMisonix, Inc. (Nasdaq: MSON) 12% HIGHER; Bioventus Inc. (Nasdaq: BVS) (Bioventus), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (Misonix), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that they have entered into a definitive agreement by which Bioventus will acquire Misonix in a cash-and-stock transaction.\nZynex, Inc. (NASDAQ: ZYXI) 11% LOWER; reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $31 million versus the consensus estimate of $31.31 million.\nZendesk (NYSE: ZEN) 7% LOWER; reported Q2 EPS of $0.13, $0.03 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $318.2 million versus the consensus estimate of $319.79 million. Zendesk sees FY2021 revenue of $1.31-1.32 billion, versus the consensus of $1.31 billion. Zendesk sees Q3 2021 revenue of $332-337 billion, versus the consensus of $335.5 billion.\nSkyworks Solutions (NASDAQ: SWKS) 5.2% LOWER; reported Q3 EPS of $2.15, $0.01 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.1 billion. Skyworks Solutions sees Q4 2021 EPS of $2.53-$2.48. Skyworks Solutions sees Q4 2021 revenue of $1.27-1.33 billion, versus the consensus of $1.22 billion.\nDexCom (NASDAQ: DXCM) 4.3% HIGHER; reported Q2 EPS of $0.76, $0.31 better than the analyst estimate of $0.45. Revenue for the quarter came in at $59.5 million versus the consensus estimate of $551.27 million. DexCom sees FY2021 revenue of $2.35-2.4 billion, versus the consensus of $2.34 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":521,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178254485,"gmtCreate":1626825163947,"gmtModify":1703765796545,"author":{"id":"3581502293537821","authorId":"3581502293537821","name":"oliviaeex","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581502293537821","authorIdStr":"3581502293537821"},"themes":[],"htmlText":"trump crumbs","listText":"trump crumbs","text":"trump crumbs","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/178254485","repostId":"2153469248","repostType":4,"isVote":1,"tweetType":1,"viewCount":908,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3571345352614779","authorId":"3571345352614779","name":"xiaobaii","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"3571345352614779","authorIdStr":"3571345352614779"},"content":"Like & Comment Please, Thank You Very Much","text":"Like & Comment Please, Thank You Very Much","html":"Like & Comment Please, Thank You Very Much"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171509050,"gmtCreate":1626748554770,"gmtModify":1703764420458,"author":{"id":"3581502293537821","authorId":"3581502293537821","name":"oliviaeex","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581502293537821","authorIdStr":"3581502293537821"},"themes":[],"htmlText":"meaning of drug deals","listText":"meaning of drug deals","text":"meaning of drug deals","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171509050","repostId":"1106612393","repostType":4,"isVote":1,"tweetType":1,"viewCount":776,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170008703,"gmtCreate":1626394073402,"gmtModify":1703759187620,"author":{"id":"3581502293537821","authorId":"3581502293537821","name":"oliviaeex","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581502293537821","authorIdStr":"3581502293537821"},"themes":[],"htmlText":"Me had moderna vaccine","listText":"Me had moderna vaccine","text":"Me had moderna vaccine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/170008703","repostId":"1140595356","repostType":4,"repost":{"id":"1140595356","kind":"news","pubTimestamp":1626387586,"share":"https://ttm.financial/m/news/1140595356?lang=&edition=fundamental","pubTime":"2021-07-16 06:19","market":"us","language":"en","title":"Why Moderna Stock Is Hitting Another Record High Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1140595356","media":"Motley Fool","summary":"The vaccine stock benefited from two positive developments.\n\nKey Points\n\nA Wall Street analyst raise","content":"<blockquote>\n The vaccine stock benefited from two positive developments.\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>A Wall Street analyst raised his price target for Moderna.</li>\n <li>A top European official also stated that a recommendation on authorization for Moderna's COVID-19 vaccine would probably be made by late next week.</li>\n</ul>\n<p><b>What happened</b></p>\n<p>Shares of<b>Moderna</b>(NASDAQ:MRNA)were jumping 4.3% as of 11:10 a.m. EDT on Thursday, hitting another record high for the stock. The bump came after Michael Yee, an analyst at<b>Jefferies</b>, increased his price target on the stock from $170 to $250.</p>\n<p>Also, Dr. Marco Cavaleri, the European Medicines Agency (EMA) head of biological health threats and vaccines strategy, stated in a press conference that a committee would likely finalize a decision on recommending authorization for Moderna's COVID-19 vaccine in children by the end of next week.</p>\n<p><b>So what</b></p>\n<p>Jefferies' higher price target for thevaccine stockreflected expectations of increased sales for Moderna's COVID-19 vaccine this year. Yee now looks for the company to up its full-year revenue guidance to $21 billion. It previously projected sales of $19.2 billion.</p>\n<p>The EMA's decision on authorization of the vaccine in immunizing children ages 12 to 17 could play a key role in driving higher sales. Although there are many more adults in the European Union than children, the pediatric market presents a big opportunity for the company.</p>\n<p>Neither of these news items, however, were compelling reasons for Moderna's shares to move higher. Jefferies' price target is actually lower than its current share price. Also, Cavaleri's comments about the pending decision by an expert committee didn't provide any hints as to what the recommendation would be.</p>\n<p><b>Now what</b></p>\n<p>The most important thing to watch with Moderna in the near term isn't the EMA committee announcement next week. Instead, it's the company's second-quarter update scheduled for Aug. 5. Moderna is likely to boost its full-year sales outlook in that update.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Is Hitting Another Record High Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Is Hitting Another Record High Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 06:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/15/why-moderna-stock-is-hitting-another-record-high-t/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The vaccine stock benefited from two positive developments.\n\nKey Points\n\nA Wall Street analyst raised his price target for Moderna.\nA top European official also stated that a recommendation on ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/15/why-moderna-stock-is-hitting-another-record-high-t/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/07/15/why-moderna-stock-is-hitting-another-record-high-t/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140595356","content_text":"The vaccine stock benefited from two positive developments.\n\nKey Points\n\nA Wall Street analyst raised his price target for Moderna.\nA top European official also stated that a recommendation on authorization for Moderna's COVID-19 vaccine would probably be made by late next week.\n\nWhat happened\nShares ofModerna(NASDAQ:MRNA)were jumping 4.3% as of 11:10 a.m. EDT on Thursday, hitting another record high for the stock. The bump came after Michael Yee, an analyst atJefferies, increased his price target on the stock from $170 to $250.\nAlso, Dr. Marco Cavaleri, the European Medicines Agency (EMA) head of biological health threats and vaccines strategy, stated in a press conference that a committee would likely finalize a decision on recommending authorization for Moderna's COVID-19 vaccine in children by the end of next week.\nSo what\nJefferies' higher price target for thevaccine stockreflected expectations of increased sales for Moderna's COVID-19 vaccine this year. Yee now looks for the company to up its full-year revenue guidance to $21 billion. It previously projected sales of $19.2 billion.\nThe EMA's decision on authorization of the vaccine in immunizing children ages 12 to 17 could play a key role in driving higher sales. Although there are many more adults in the European Union than children, the pediatric market presents a big opportunity for the company.\nNeither of these news items, however, were compelling reasons for Moderna's shares to move higher. Jefferies' price target is actually lower than its current share price. Also, Cavaleri's comments about the pending decision by an expert committee didn't provide any hints as to what the recommendation would be.\nNow what\nThe most important thing to watch with Moderna in the near term isn't the EMA committee announcement next week. Instead, it's the company's second-quarter update scheduled for Aug. 5. Moderna is likely to boost its full-year sales outlook in that update.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1041,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":377940842,"gmtCreate":1619491868586,"gmtModify":1704724841890,"author":{"id":"3581502293537821","authorId":"3581502293537821","name":"oliviaeex","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581502293537821","authorIdStr":"3581502293537821"},"themes":[],"htmlText":"Netflix &gt; Disney+","listText":"Netflix &gt; Disney+","text":"Netflix > Disney+","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/377940842","repostId":"2130312472","repostType":4,"isVote":1,"tweetType":1,"viewCount":740,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":376735065,"gmtCreate":1619147858857,"gmtModify":1704720383043,"author":{"id":"3581502293537821","authorId":"3581502293537821","name":"oliviaeex","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581502293537821","authorIdStr":"3581502293537821"},"themes":[],"htmlText":"like for like","listText":"like for like","text":"like for like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/376735065","repostId":"1145865439","repostType":4,"isVote":1,"tweetType":1,"viewCount":552,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":376735065,"gmtCreate":1619147858857,"gmtModify":1704720383043,"author":{"id":"3581502293537821","authorId":"3581502293537821","name":"oliviaeex","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581502293537821","authorIdStr":"3581502293537821"},"themes":[],"htmlText":"like for like","listText":"like for like","text":"like for like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/376735065","repostId":"1145865439","repostType":4,"repost":{"id":"1145865439","kind":"news","pubTimestamp":1619146694,"share":"https://ttm.financial/m/news/1145865439?lang=&edition=fundamental","pubTime":"2021-04-23 10:58","market":"us","language":"en","title":"Intel’s new CEO has another big problem to fix","url":"https://stock-news.laohu8.com/highlight/detail?id=1145865439","media":"MarketWatch","summary":"Gelsinger says sharp drop in data-center chip sales is a temporary blip, but analysts wonder if riva","content":"<blockquote>\n Gelsinger says sharp drop in data-center chip sales is a temporary blip, but analysts wonder if rival AMD is gaining ground.\n</blockquote>\n<p>Intel Corp.’s new chief executive, Pat Gelsinger, has another urgent problem to deal with, in addition to restoring the chip giant’s manufacturing business to its former glory.</p>\n<p>In its earning report Thursday, Intel INTC, -1.77% said its highly profitable business of selling chips to data-center customers had its worst quarter in a year, with revenue dropping an unexpected 20%, which included a 14% drop in average selling prices. Overall, the company’s total revenue of $19.7 billion came in better than expected, even while it was down 1% year over year.</p>\n<p>But the surprise double-digit drop in data-center sales unsettled investors, and Intel shares slipped more than 2% in after-hours trading, at one point falling to $60.61 in the extended session.</p>\n<p>The state of the data-center business was the dominant topic on the earnings call Thursday afternoon, during which some analysts tried to glean if competitive pressure from rival Advanced Micro Devices Inc. AMD, -3.12% was having an effect.</p>\n<p>Intel executives tried to bat away that notion, saying that over half of the drop in average selling prices was due to strong sales of lower-priced network system-on-a-chip products and other product-mix issues. In addition, Intel was seeing a very tough comparison to the first quarter of 2020, when revenue soared 23% overall and data-center revenue surged 34%. They also said many customers were digesting past purchases.</p>\n<p>But it is that area that was left mostly undiscussed, with analysts suspecting the sizeable drop in average selling price may be due to competition from AMD. Intel cited higher startup expenses for its newest manufacturing nodes, as it moves to 10-nanometer geometries its next generation.</p>\n<p>“Can you help us understand why you’re comfortable that this is digestion and not something more, like cloud guys going to more internal solutions or solutions away from Intel?” asked John Pitzer, a Credit Suisse analyst. “I know you have another hard compare year-over-year on Q2, but what gives you confidence that this is digestion and not something more?”</p>\n<p>Gelsinger noted that the company works very closely with its customers and the supply chain, and is building its forecasts based on data from these relationships.</p>\n<p>“We know what their inventory levels are. These are very intimate relationships,” Gelsinger said. “So I’d just say at that level, we’re confident when we speak that what they’re doing, and what we’re going to see in the future, and how they’re digesting and deploying the products that we delivered to them last year, are now ramping in.”</p>\n<p>Even so, not everyone is buying it. Patrick Moorhead, an analyst with Moor Insights, said in a brief note that he attributed the lower prices in the data-center group “to a combination to mix shift lower and competitive pressure. “</p>\n<p>With data center as such a big profit driver for Intel, investors are hoping that Gelsinger is right and that after a brief digestion period, those sales will come back. Next Tuesday, when AMD reports its earnings, should provide another data point. But it may be that Gelsinger not only has a manufacturing issue to work on and build up again, but an increasingly stronger opponent in AMD.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title> Intel’s new CEO has another big problem to fix</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n Intel’s new CEO has another big problem to fix\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 10:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/intels-new-ceo-has-another-big-problem-to-fix-11619137489?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gelsinger says sharp drop in data-center chip sales is a temporary blip, but analysts wonder if rival AMD is gaining ground.\n\nIntel Corp.’s new chief executive, Pat Gelsinger, has another urgent ...</p>\n\n<a href=\"https://www.marketwatch.com/story/intels-new-ceo-has-another-big-problem-to-fix-11619137489?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTC":"英特尔"},"source_url":"https://www.marketwatch.com/story/intels-new-ceo-has-another-big-problem-to-fix-11619137489?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1145865439","content_text":"Gelsinger says sharp drop in data-center chip sales is a temporary blip, but analysts wonder if rival AMD is gaining ground.\n\nIntel Corp.’s new chief executive, Pat Gelsinger, has another urgent problem to deal with, in addition to restoring the chip giant’s manufacturing business to its former glory.\nIn its earning report Thursday, Intel INTC, -1.77% said its highly profitable business of selling chips to data-center customers had its worst quarter in a year, with revenue dropping an unexpected 20%, which included a 14% drop in average selling prices. Overall, the company’s total revenue of $19.7 billion came in better than expected, even while it was down 1% year over year.\nBut the surprise double-digit drop in data-center sales unsettled investors, and Intel shares slipped more than 2% in after-hours trading, at one point falling to $60.61 in the extended session.\nThe state of the data-center business was the dominant topic on the earnings call Thursday afternoon, during which some analysts tried to glean if competitive pressure from rival Advanced Micro Devices Inc. AMD, -3.12% was having an effect.\nIntel executives tried to bat away that notion, saying that over half of the drop in average selling prices was due to strong sales of lower-priced network system-on-a-chip products and other product-mix issues. In addition, Intel was seeing a very tough comparison to the first quarter of 2020, when revenue soared 23% overall and data-center revenue surged 34%. They also said many customers were digesting past purchases.\nBut it is that area that was left mostly undiscussed, with analysts suspecting the sizeable drop in average selling price may be due to competition from AMD. Intel cited higher startup expenses for its newest manufacturing nodes, as it moves to 10-nanometer geometries its next generation.\n“Can you help us understand why you’re comfortable that this is digestion and not something more, like cloud guys going to more internal solutions or solutions away from Intel?” asked John Pitzer, a Credit Suisse analyst. “I know you have another hard compare year-over-year on Q2, but what gives you confidence that this is digestion and not something more?”\nGelsinger noted that the company works very closely with its customers and the supply chain, and is building its forecasts based on data from these relationships.\n“We know what their inventory levels are. These are very intimate relationships,” Gelsinger said. “So I’d just say at that level, we’re confident when we speak that what they’re doing, and what we’re going to see in the future, and how they’re digesting and deploying the products that we delivered to them last year, are now ramping in.”\nEven so, not everyone is buying it. Patrick Moorhead, an analyst with Moor Insights, said in a brief note that he attributed the lower prices in the data-center group “to a combination to mix shift lower and competitive pressure. “\nWith data center as such a big profit driver for Intel, investors are hoping that Gelsinger is right and that after a brief digestion period, those sales will come back. Next Tuesday, when AMD reports its earnings, should provide another data point. But it may be that Gelsinger not only has a manufacturing issue to work on and build up again, but an increasingly stronger opponent in AMD.","news_type":1},"isVote":1,"tweetType":1,"viewCount":552,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170008703,"gmtCreate":1626394073402,"gmtModify":1703759187620,"author":{"id":"3581502293537821","authorId":"3581502293537821","name":"oliviaeex","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581502293537821","authorIdStr":"3581502293537821"},"themes":[],"htmlText":"Me had moderna vaccine","listText":"Me had moderna vaccine","text":"Me had moderna vaccine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/170008703","repostId":"1140595356","repostType":4,"repost":{"id":"1140595356","kind":"news","pubTimestamp":1626387586,"share":"https://ttm.financial/m/news/1140595356?lang=&edition=fundamental","pubTime":"2021-07-16 06:19","market":"us","language":"en","title":"Why Moderna Stock Is Hitting Another Record High Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1140595356","media":"Motley Fool","summary":"The vaccine stock benefited from two positive developments.\n\nKey Points\n\nA Wall Street analyst raise","content":"<blockquote>\n The vaccine stock benefited from two positive developments.\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>A Wall Street analyst raised his price target for Moderna.</li>\n <li>A top European official also stated that a recommendation on authorization for Moderna's COVID-19 vaccine would probably be made by late next week.</li>\n</ul>\n<p><b>What happened</b></p>\n<p>Shares of<b>Moderna</b>(NASDAQ:MRNA)were jumping 4.3% as of 11:10 a.m. EDT on Thursday, hitting another record high for the stock. The bump came after Michael Yee, an analyst at<b>Jefferies</b>, increased his price target on the stock from $170 to $250.</p>\n<p>Also, Dr. Marco Cavaleri, the European Medicines Agency (EMA) head of biological health threats and vaccines strategy, stated in a press conference that a committee would likely finalize a decision on recommending authorization for Moderna's COVID-19 vaccine in children by the end of next week.</p>\n<p><b>So what</b></p>\n<p>Jefferies' higher price target for thevaccine stockreflected expectations of increased sales for Moderna's COVID-19 vaccine this year. Yee now looks for the company to up its full-year revenue guidance to $21 billion. It previously projected sales of $19.2 billion.</p>\n<p>The EMA's decision on authorization of the vaccine in immunizing children ages 12 to 17 could play a key role in driving higher sales. Although there are many more adults in the European Union than children, the pediatric market presents a big opportunity for the company.</p>\n<p>Neither of these news items, however, were compelling reasons for Moderna's shares to move higher. Jefferies' price target is actually lower than its current share price. Also, Cavaleri's comments about the pending decision by an expert committee didn't provide any hints as to what the recommendation would be.</p>\n<p><b>Now what</b></p>\n<p>The most important thing to watch with Moderna in the near term isn't the EMA committee announcement next week. Instead, it's the company's second-quarter update scheduled for Aug. 5. Moderna is likely to boost its full-year sales outlook in that update.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Is Hitting Another Record High Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Is Hitting Another Record High Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 06:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/15/why-moderna-stock-is-hitting-another-record-high-t/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The vaccine stock benefited from two positive developments.\n\nKey Points\n\nA Wall Street analyst raised his price target for Moderna.\nA top European official also stated that a recommendation on ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/15/why-moderna-stock-is-hitting-another-record-high-t/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/07/15/why-moderna-stock-is-hitting-another-record-high-t/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140595356","content_text":"The vaccine stock benefited from two positive developments.\n\nKey Points\n\nA Wall Street analyst raised his price target for Moderna.\nA top European official also stated that a recommendation on authorization for Moderna's COVID-19 vaccine would probably be made by late next week.\n\nWhat happened\nShares ofModerna(NASDAQ:MRNA)were jumping 4.3% as of 11:10 a.m. EDT on Thursday, hitting another record high for the stock. The bump came after Michael Yee, an analyst atJefferies, increased his price target on the stock from $170 to $250.\nAlso, Dr. Marco Cavaleri, the European Medicines Agency (EMA) head of biological health threats and vaccines strategy, stated in a press conference that a committee would likely finalize a decision on recommending authorization for Moderna's COVID-19 vaccine in children by the end of next week.\nSo what\nJefferies' higher price target for thevaccine stockreflected expectations of increased sales for Moderna's COVID-19 vaccine this year. Yee now looks for the company to up its full-year revenue guidance to $21 billion. It previously projected sales of $19.2 billion.\nThe EMA's decision on authorization of the vaccine in immunizing children ages 12 to 17 could play a key role in driving higher sales. Although there are many more adults in the European Union than children, the pediatric market presents a big opportunity for the company.\nNeither of these news items, however, were compelling reasons for Moderna's shares to move higher. Jefferies' price target is actually lower than its current share price. Also, Cavaleri's comments about the pending decision by an expert committee didn't provide any hints as to what the recommendation would be.\nNow what\nThe most important thing to watch with Moderna in the near term isn't the EMA committee announcement next week. Instead, it's the company's second-quarter update scheduled for Aug. 5. Moderna is likely to boost its full-year sales outlook in that update.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1041,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808557517,"gmtCreate":1627603432839,"gmtModify":1703493081019,"author":{"id":"3581502293537821","authorId":"3581502293537821","name":"oliviaeex","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581502293537821","authorIdStr":"3581502293537821"},"themes":[],"htmlText":"PHAR IS DA WAY","listText":"PHAR IS DA WAY","text":"PHAR IS DA WAY","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/808557517","repostId":"2155182860","repostType":4,"isVote":1,"tweetType":1,"viewCount":521,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178254485,"gmtCreate":1626825163947,"gmtModify":1703765796545,"author":{"id":"3581502293537821","authorId":"3581502293537821","name":"oliviaeex","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581502293537821","authorIdStr":"3581502293537821"},"themes":[],"htmlText":"trump crumbs","listText":"trump crumbs","text":"trump crumbs","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/178254485","repostId":"2153469248","repostType":4,"repost":{"id":"2153469248","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626824760,"share":"https://ttm.financial/m/news/2153469248?lang=&edition=fundamental","pubTime":"2021-07-21 07:46","market":"us","language":"en","title":"U.S. banking regulator moves to scrap Trump-era fair lending rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2153469248","media":"Reuters","summary":"WASHINGTON, July 20 (Reuters) - A leading U.S. bank regulator announced Tuesday it will propose resc","content":"<p>WASHINGTON, July 20 (Reuters) - A leading U.S. bank regulator announced Tuesday it will propose rescinding a 2020 update to a fair lending rule, and instead will work with other regulators on establishing a joint rule.</p>\n<p>The Office of the Comptroller of the Currency said it was moving to scrap the previous update to the Community Reinvestment Act rules, saying uniform action across regulators is preferred. In a joint statement, the OCC, Federal Reserve and Federal Deposit Insurance Corp said they were committed to a joint rule-writing effort to update requirements for the 1977 fair lending law.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. banking regulator moves to scrap Trump-era fair lending rules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. banking regulator moves to scrap Trump-era fair lending rules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-21 07:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>WASHINGTON, July 20 (Reuters) - A leading U.S. bank regulator announced Tuesday it will propose rescinding a 2020 update to a fair lending rule, and instead will work with other regulators on establishing a joint rule.</p>\n<p>The Office of the Comptroller of the Currency said it was moving to scrap the previous update to the Community Reinvestment Act rules, saying uniform action across regulators is preferred. In a joint statement, the OCC, Federal Reserve and Federal Deposit Insurance Corp said they were committed to a joint rule-writing effort to update requirements for the 1977 fair lending law.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153469248","content_text":"WASHINGTON, July 20 (Reuters) - A leading U.S. bank regulator announced Tuesday it will propose rescinding a 2020 update to a fair lending rule, and instead will work with other regulators on establishing a joint rule.\nThe Office of the Comptroller of the Currency said it was moving to scrap the previous update to the Community Reinvestment Act rules, saying uniform action across regulators is preferred. In a joint statement, the OCC, Federal Reserve and Federal Deposit Insurance Corp said they were committed to a joint rule-writing effort to update requirements for the 1977 fair lending law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":908,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3571345352614779","authorId":"3571345352614779","name":"xiaobaii","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"3571345352614779","authorIdStr":"3571345352614779"},"content":"Like & Comment Please, Thank You Very Much","text":"Like & Comment Please, Thank You Very Much","html":"Like & Comment Please, Thank You Very Much"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888241656,"gmtCreate":1631502260075,"gmtModify":1676530559601,"author":{"id":"3581502293537821","authorId":"3581502293537821","name":"oliviaeex","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581502293537821","authorIdStr":"3581502293537821"},"themes":[],"htmlText":"oh dear","listText":"oh dear","text":"oh dear","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/888241656","repostId":"1104432279","repostType":4,"repost":{"id":"1104432279","kind":"news","pubTimestamp":1631502093,"share":"https://ttm.financial/m/news/1104432279?lang=&edition=fundamental","pubTime":"2021-09-13 11:01","market":"us","language":"en","title":"Ford is ending production in India and taking a $2 billion hit in the process","url":"https://stock-news.laohu8.com/highlight/detail?id=1104432279","media":"CNN","summary":"New York/New Delhi (CNN Business)Ford is ending production in India and taking a hit of $2 billion a","content":"<p>New York/New Delhi (CNN Business)Ford is ending production in India and taking a hit of $2 billion as it retrenches from a market that has been almost impossible for American automakers to break into.</p>\n<p>In an announcement Thursday, the company said that roughly 4,000 employees will be laid off and manufacturing will end immediately. CEO Jim Farley said the move was \"difficult but necessary\" to achieve long-term growth.</p>\n<p>\"Despite investing significantly in India, Ford has accumulated more than $2 billion of operating losses over the past 10 years and demand for new vehicles has been much weaker than forecast,\" Farley said.</p>\n<p>Ford's India head, Anurag Mehrotra, said that the unit has not been able to find a \"sustainable path forward to long-term profitability that includes in-country vehicle manufacturing.\" He added that the decision was \"reinforced by years of accumulated losses, persistent industry overcapacity and lack of expected growth in India's car market.\"</p>\n<p>Two Ford plants in the cities of Sanand and Chennai will shutter in the coming months and the company will \"work closely\" with employees affected by the closures.</p>\n<p>Ford (F) has long struggled in India, which was the world's fifth largest auto market last year. The automaker began operations there in 1995, and has invested more than $2 billion in the country over the past 25 years.</p>\n<p>But it has barely picked up any market share. Ford's control of the market stood at roughly 1.8% in July, down from nearly 2.1% a year ago, according the Federation of Automobile Dealers Associations, a body representing automobile dealers.</p>\n<p>Top carmaker Maruti Suzuki — an Indian firm owned by Japan's Suzuki Motor Corporation — had nearly 45% market share in July, while South Korea's Hyundai (HYMTF) controlled 17%.</p>\n<p>Even with those challenges, the decision to end production surprised some industry experts.</p>\n<p>\"It has come as a shock since they had invested so much in India,\" said Hormazd Sorabjee, editor of Autocar India. He attributed Ford's problems to the company's inability to \"get the Indian psyche,\" saying that the automaker had spent money in areas that customers did not appreciate.</p>\n<p>Sorabjee pointed, for example, to the Sanand plant, which he argued was too costly. (The factory cost $1 billion and opened in 2015, according to Reuters.)</p>\n<p>\"It is built like a Taj Mahal,\" he added. \"The western manufacturers just don't think frugal.\"</p>\n<p>In 2019, Ford reached a deal with local rival Mahindra to transfer most of its Indian business into a new joint venture, but the deal fell apart late last year. The companies cited \"fundamental changes in global economic and business conditions\" caused in part by the pandemic.</p>\n<p>Ford is the latest US carmaker to cut back its India business in recent years. General Motors (GM) announced in 2017 that it would stop selling cars in the country.</p>\n<p>\"While India appears to be a very promising market from outside, it is also a really tough one,\" said Ruchit Agarwal, co-founder and CFO of CARS24, an online marketplace for used cars. He called the market \"price-sensitive,\" adding that the average selling price of a new car is about $10,000.</p>\n<p>That cheap car market is \"locked by a handful of manufacturers\" who have figured out how to operate in Asia's third largest economy, Sorabjee said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ford is ending production in India and taking a $2 billion hit in the process</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFord is ending production in India and taking a $2 billion hit in the process\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-13 11:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://edition.cnn.com/2021/09/09/business/ford-india-production/index.html><strong>CNN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New York/New Delhi (CNN Business)Ford is ending production in India and taking a hit of $2 billion as it retrenches from a market that has been almost impossible for American automakers to break into....</p>\n\n<a href=\"https://edition.cnn.com/2021/09/09/business/ford-india-production/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"F":"福特汽车"},"source_url":"https://edition.cnn.com/2021/09/09/business/ford-india-production/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104432279","content_text":"New York/New Delhi (CNN Business)Ford is ending production in India and taking a hit of $2 billion as it retrenches from a market that has been almost impossible for American automakers to break into.\nIn an announcement Thursday, the company said that roughly 4,000 employees will be laid off and manufacturing will end immediately. CEO Jim Farley said the move was \"difficult but necessary\" to achieve long-term growth.\n\"Despite investing significantly in India, Ford has accumulated more than $2 billion of operating losses over the past 10 years and demand for new vehicles has been much weaker than forecast,\" Farley said.\nFord's India head, Anurag Mehrotra, said that the unit has not been able to find a \"sustainable path forward to long-term profitability that includes in-country vehicle manufacturing.\" He added that the decision was \"reinforced by years of accumulated losses, persistent industry overcapacity and lack of expected growth in India's car market.\"\nTwo Ford plants in the cities of Sanand and Chennai will shutter in the coming months and the company will \"work closely\" with employees affected by the closures.\nFord (F) has long struggled in India, which was the world's fifth largest auto market last year. The automaker began operations there in 1995, and has invested more than $2 billion in the country over the past 25 years.\nBut it has barely picked up any market share. Ford's control of the market stood at roughly 1.8% in July, down from nearly 2.1% a year ago, according the Federation of Automobile Dealers Associations, a body representing automobile dealers.\nTop carmaker Maruti Suzuki — an Indian firm owned by Japan's Suzuki Motor Corporation — had nearly 45% market share in July, while South Korea's Hyundai (HYMTF) controlled 17%.\nEven with those challenges, the decision to end production surprised some industry experts.\n\"It has come as a shock since they had invested so much in India,\" said Hormazd Sorabjee, editor of Autocar India. He attributed Ford's problems to the company's inability to \"get the Indian psyche,\" saying that the automaker had spent money in areas that customers did not appreciate.\nSorabjee pointed, for example, to the Sanand plant, which he argued was too costly. (The factory cost $1 billion and opened in 2015, according to Reuters.)\n\"It is built like a Taj Mahal,\" he added. \"The western manufacturers just don't think frugal.\"\nIn 2019, Ford reached a deal with local rival Mahindra to transfer most of its Indian business into a new joint venture, but the deal fell apart late last year. The companies cited \"fundamental changes in global economic and business conditions\" caused in part by the pandemic.\nFord is the latest US carmaker to cut back its India business in recent years. General Motors (GM) announced in 2017 that it would stop selling cars in the country.\n\"While India appears to be a very promising market from outside, it is also a really tough one,\" said Ruchit Agarwal, co-founder and CFO of CARS24, an online marketplace for used cars. He called the market \"price-sensitive,\" adding that the average selling price of a new car is about $10,000.\nThat cheap car market is \"locked by a handful of manufacturers\" who have figured out how to operate in Asia's third largest economy, Sorabjee said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":764,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171509050,"gmtCreate":1626748554770,"gmtModify":1703764420458,"author":{"id":"3581502293537821","authorId":"3581502293537821","name":"oliviaeex","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581502293537821","authorIdStr":"3581502293537821"},"themes":[],"htmlText":"meaning of drug deals","listText":"meaning of drug deals","text":"meaning of drug deals","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171509050","repostId":"1106612393","repostType":4,"repost":{"id":"1106612393","kind":"news","pubTimestamp":1626748079,"share":"https://ttm.financial/m/news/1106612393?lang=&edition=fundamental","pubTime":"2021-07-20 10:27","market":"us","language":"en","title":"$26 Billion Opioid Settlement Among States and Drug Industry Expected This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1106612393","media":"WSJ","summary":"Thousands of opioid-crisis lawsuits filed against major drugmakers and distributors are nearing a co","content":"<p>Thousands of opioid-crisis lawsuits filed against major drugmakers and distributors are nearing a conclusion, with the outlines of a $26 billion deal between states and four companies expected to be announced this week and a $1 billion settlement to resolve some of <a href=\"https://laohu8.com/S/NWY\">New York</a>’s claims likely on Tuesday, people familiar with the matter said.</p>\n<p>Drug distributors&nbsp;<a href=\"https://laohu8.com/S/ABC\">AmerisourceBergen</a>&nbsp;Corp., <a href=\"https://laohu8.com/S/CAH\">Cardinal Health</a> Inc. and&nbsp;<a href=\"https://laohu8.com/S/MCK\">McKesson</a>&nbsp;Corp.and manufacturer&nbsp;Johnson &amp; Johnson&nbsp;have been negotiating the $26 billion settlement for more than two years as a way to resolve thousands of lawsuits filed by state and local governments blaming them for helping fuel the nation’s opioid epidemic. From 1999 to 2019, the nation lost nearly half a million people to overdoses of prescription and illegal opioids, according to federal data.</p>\n<p>Under the contours of the deal, states and municipalities still have several months to sign on, and the amount ultimately paid will depend on how many participate, the people familiar with the talks said. The companies can also still walk away if they aren’t satisfied with the number of states and governments that join, the people said.</p>\n<p><a href=\"https://laohu8.com/S/NYRT\">New York</a>, meanwhile, has struck a more than $1 billion deal with AmerisourceBergen, <a href=\"https://laohu8.com/S/CFNL\">Cardinal</a> and McKesson midway through a trial against those companies and four other pharmaceutical firms,&nbsp; some of the people said. That deal is expected to be announced Tuesday, they said, and would remove AmerisourceBergen, Cardinal and McKesson from the trial.</p>\n<p>Johnson &amp; Johnson already settled with <a href=\"https://laohu8.com/S/NGD\">New</a> York for $263 million ahead of the trial.</p>\n<p>The larger settlement, if finalized, would remove an albatross for companies that for years have faced allegations from plaintiffs’ lawyers, families and governments that they played a role in sparking and expanding opioid addiction. Uncertainty over the litigation has weighed down some companies’ stocks. Questions about resolving the lawsuits have dogged executives on earnings calls and at investor conferences and resulted in chief executives testifying before Congress.</p>\n<p>Bloomberg <a href=\"https://laohu8.com/S/NWS\">News</a> reported the timing of the $26 billion settlement Monday evening.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>$26 Billion Opioid Settlement Among States and Drug Industry Expected This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n$26 Billion Opioid Settlement Among States and Drug Industry Expected This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 10:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/26-billion-opioid-settlement-among-states-and-drug-industry-expected-this-week-11626745448?mod=hp_lead_pos2><strong>WSJ</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Thousands of opioid-crisis lawsuits filed against major drugmakers and distributors are nearing a conclusion, with the outlines of a $26 billion deal between states and four companies expected to be ...</p>\n\n<a href=\"https://www.wsj.com/articles/26-billion-opioid-settlement-among-states-and-drug-industry-expected-this-week-11626745448?mod=hp_lead_pos2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","MCK":"麦克森药物批发","CAH":"卡地纳健康"},"source_url":"https://www.wsj.com/articles/26-billion-opioid-settlement-among-states-and-drug-industry-expected-this-week-11626745448?mod=hp_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106612393","content_text":"Thousands of opioid-crisis lawsuits filed against major drugmakers and distributors are nearing a conclusion, with the outlines of a $26 billion deal between states and four companies expected to be announced this week and a $1 billion settlement to resolve some of New York’s claims likely on Tuesday, people familiar with the matter said.\nDrug distributors AmerisourceBergen Corp., Cardinal Health Inc. and McKesson Corp.and manufacturer Johnson & Johnson have been negotiating the $26 billion settlement for more than two years as a way to resolve thousands of lawsuits filed by state and local governments blaming them for helping fuel the nation’s opioid epidemic. From 1999 to 2019, the nation lost nearly half a million people to overdoses of prescription and illegal opioids, according to federal data.\nUnder the contours of the deal, states and municipalities still have several months to sign on, and the amount ultimately paid will depend on how many participate, the people familiar with the talks said. The companies can also still walk away if they aren’t satisfied with the number of states and governments that join, the people said.\nNew York, meanwhile, has struck a more than $1 billion deal with AmerisourceBergen, Cardinal and McKesson midway through a trial against those companies and four other pharmaceutical firms,  some of the people said. That deal is expected to be announced Tuesday, they said, and would remove AmerisourceBergen, Cardinal and McKesson from the trial.\nJohnson & Johnson already settled with New York for $263 million ahead of the trial.\nThe larger settlement, if finalized, would remove an albatross for companies that for years have faced allegations from plaintiffs’ lawyers, families and governments that they played a role in sparking and expanding opioid addiction. Uncertainty over the litigation has weighed down some companies’ stocks. Questions about resolving the lawsuits have dogged executives on earnings calls and at investor conferences and resulted in chief executives testifying before Congress.\nBloomberg News reported the timing of the $26 billion settlement Monday evening.","news_type":1},"isVote":1,"tweetType":1,"viewCount":776,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":377940842,"gmtCreate":1619491868586,"gmtModify":1704724841890,"author":{"id":"3581502293537821","authorId":"3581502293537821","name":"oliviaeex","avatar":"https://static.tigerbbs.com/bb5c135ec9104a6b25b19b233db0f3bc","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581502293537821","authorIdStr":"3581502293537821"},"themes":[],"htmlText":"Netflix &gt; Disney+","listText":"Netflix &gt; Disney+","text":"Netflix > Disney+","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/377940842","repostId":"2130312472","repostType":4,"repost":{"id":"2130312472","kind":"highlight","pubTimestamp":1619489248,"share":"https://ttm.financial/m/news/2130312472?lang=&edition=fundamental","pubTime":"2021-04-27 10:07","market":"us","language":"en","title":"Netflix's Pandemic Boost Is Over -- but Here's Why I'm Not Worried","url":"https://stock-news.laohu8.com/highlight/detail?id=2130312472","media":"Motley Fool","summary":"After a historic year for the business, there's still a long way to go. Investors need to look beneath the headline numbers.","content":"<p><b>Netflix</b>&nbsp;(NASDAQ:NFLX)&nbsp;reported first-quarter 2021 results last week and disappointed many analysts and investors with its subscriber numbers. After adding an incredible 37 million members last year, the streaming giant&nbsp;only managed to sign up 4 million in the first three months of this year.&nbsp;</p>\n<p>This missed estimates by&nbsp;management&nbsp;(6 million) and Wall&nbsp;Street (6.2 million), causing the stock price to fall about 8% since Tuesday's market close. To make matters worse, the company is forecasting just 1 million subscriber additions in the current quarter.&nbsp;</p>\n<p>The coronavirus pandemic led to a surge in Netflix's business in 2020, but now investors are concerned that growth going forward will slow as people spend more time away from home and competition in the space heats up.&nbsp;</p>\n<p>If we take a step back for a second, though, we'll see that Netflix is doing just fine. Here's a tip for investors regarding this latest news: don't worry.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2fe4bab9776871d3159b58fe391a7568\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Still the leader in streaming entertainment&nbsp;</h2>\n<p>Revenue in the quarter still increased 24%&nbsp;year over year as a result of pricing&nbsp;increases in the U.S. late last year. And average revenue per user (ARPU), a key metric for any subscription-based business,&nbsp;rose&nbsp;6%. Netflix claimed higher&nbsp;engagement&nbsp;as well as lower member churn in the quarter compared to last year, further calming&nbsp;investor fears. These are still very healthy numbers.&nbsp;</p>\n<p>Operating income nearly&nbsp;doubled&nbsp;from Q1 2020 due to lower content spend. But normal production&nbsp;schedules&nbsp;are now up and running in all regions except Brazil and India. And the company expects to spend $17&nbsp;billion on content this year, more than the $12.5 billion&nbsp;it spent in 2020.&nbsp;</p>\n<p>This will pressure profits and cash flow, but it will help drive subscriber growth in the second half of the year as a heavier slate of new releases comes out. Furthermore, none of the other competing services spends anywhere close to what Netflix does, cementing its first-mover advantage in the industry as it spreads those costs out over a massive subscriber base.&nbsp;</p>\n<p>To add to the discussion on competition, in the most recent&nbsp;earnings call, co-founder and co-CEO Reed Hastings highlighted that other, newer services entering the market were not to blame for the subpar quarter. \"Our largest competitor for TV viewing time is linear TV, our second largest is [<b>Alphabet</b>'s] YouTube, which is considerably larger than Netflix in viewing time and [<b>Walt</b>] <b>Disney</b> is considerably smaller,\" he said.&nbsp;</p>\n<p>I tend to agree with him. And if newcomers streaming services like Disney+ and <b>AT&amp;T</b>'s HBO Max give you pause, then consider this: About 90%&nbsp;of customers to these two services also subscribe to Netflix, while only 20% and 50% of Netflix subscribers are also customers of HBO Max and Disney+, respectively. This demonstrates the value proposition Netflix offers.&nbsp;</p>\n<h2>The final word&nbsp;</h2>\n<p>Netflix is still the leader in streaming. As it continues to spend billions on award-winning content, membership will keep rising over time, particularly overseas. Even if the company only adds 9 million total customers during the rest of the year, that would still equate to 50 million over the last two years. Investors should take this pessimism surrounding the stock (and the short-term price drop) as an opportunity to buy shares.&nbsp;</p>\n<p>Additionally, the company is on the verge of being&nbsp;sustainably cash-flow-positive, with planned share repurchases supporting shareholder returns. Although the pandemic boost has faded, investors don't need to worry.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Netflix's Pandemic Boost Is Over -- but Here's Why I'm Not Worried</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNetflix's Pandemic Boost Is Over -- but Here's Why I'm Not Worried\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-27 10:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/26/netflix-pandemic-boost-over-why-im-not-worried/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Netflix (NASDAQ:NFLX) reported first-quarter 2021 results last week and disappointed many analysts and investors with its subscriber numbers. After adding an incredible 37 million members last year, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/26/netflix-pandemic-boost-over-why-im-not-worried/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞"},"source_url":"https://www.fool.com/investing/2021/04/26/netflix-pandemic-boost-over-why-im-not-worried/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2130312472","content_text":"Netflix (NASDAQ:NFLX) reported first-quarter 2021 results last week and disappointed many analysts and investors with its subscriber numbers. After adding an incredible 37 million members last year, the streaming giant only managed to sign up 4 million in the first three months of this year. \nThis missed estimates by management (6 million) and Wall Street (6.2 million), causing the stock price to fall about 8% since Tuesday's market close. To make matters worse, the company is forecasting just 1 million subscriber additions in the current quarter. \nThe coronavirus pandemic led to a surge in Netflix's business in 2020, but now investors are concerned that growth going forward will slow as people spend more time away from home and competition in the space heats up. \nIf we take a step back for a second, though, we'll see that Netflix is doing just fine. Here's a tip for investors regarding this latest news: don't worry. \nImage source: Getty Images.\nStill the leader in streaming entertainment \nRevenue in the quarter still increased 24% year over year as a result of pricing increases in the U.S. late last year. And average revenue per user (ARPU), a key metric for any subscription-based business, rose 6%. Netflix claimed higher engagement as well as lower member churn in the quarter compared to last year, further calming investor fears. These are still very healthy numbers. \nOperating income nearly doubled from Q1 2020 due to lower content spend. But normal production schedules are now up and running in all regions except Brazil and India. And the company expects to spend $17 billion on content this year, more than the $12.5 billion it spent in 2020. \nThis will pressure profits and cash flow, but it will help drive subscriber growth in the second half of the year as a heavier slate of new releases comes out. Furthermore, none of the other competing services spends anywhere close to what Netflix does, cementing its first-mover advantage in the industry as it spreads those costs out over a massive subscriber base. \nTo add to the discussion on competition, in the most recent earnings call, co-founder and co-CEO Reed Hastings highlighted that other, newer services entering the market were not to blame for the subpar quarter. \"Our largest competitor for TV viewing time is linear TV, our second largest is [Alphabet's] YouTube, which is considerably larger than Netflix in viewing time and [Walt] Disney is considerably smaller,\" he said. \nI tend to agree with him. And if newcomers streaming services like Disney+ and AT&T's HBO Max give you pause, then consider this: About 90% of customers to these two services also subscribe to Netflix, while only 20% and 50% of Netflix subscribers are also customers of HBO Max and Disney+, respectively. This demonstrates the value proposition Netflix offers. \nThe final word \nNetflix is still the leader in streaming. As it continues to spend billions on award-winning content, membership will keep rising over time, particularly overseas. Even if the company only adds 9 million total customers during the rest of the year, that would still equate to 50 million over the last two years. Investors should take this pessimism surrounding the stock (and the short-term price drop) as an opportunity to buy shares. \nAdditionally, the company is on the verge of being sustainably cash-flow-positive, with planned share repurchases supporting shareholder returns. Although the pandemic boost has faded, investors don't need to worry.","news_type":1},"isVote":1,"tweetType":1,"viewCount":740,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}